The base award is valued at $5.4m over 17 months; with provisions for renewal at the NCI’s option. The contract is partly funded by the American Recovery and Reinvestment Act.
Asterand CEO Martyn Coombs said that they are honored that the NCI has selected Asterand as a partner for this prestigious project. The TCGA will revolutionise the molecular understanding of cancer.
“This project emphasises the significant impact of well characterised and high quality human specimens on modern biomedical research. We feel privileged to play a role in enabling the NCI to advance this critical research and accelerate the development of new treatments and diagnostic tools for this disease,” Coombs said.